The selective tyrosine kinase inhibitor Imatinib can block this kinase activity by occupying ATP binding site of Bcr/Abl and inhibit CML cell growth effectively [1]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.